LLY 10-K Annual Report Dec. 31, 2021 | Alphaminr

LLY 10-K Fiscal year ended Dec. 31, 2021

ELI LILLY & CO
10-Ks and 10-Qs
10-Q
Quarter ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-K
Fiscal year ended Dec. 31, 2023
10-Q
Quarter ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-K
Fiscal year ended Dec. 31, 2022
10-Q
Quarter ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-K
Fiscal year ended Dec. 31, 2021
10-Q
Quarter ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-K
Fiscal year ended Dec. 31, 2020
10-Q
Quarter ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-K
Fiscal year ended Dec. 31, 2019
10-Q
Quarter ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-K
Fiscal year ended Dec. 31, 2018
10-Q
Quarter ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-K
Fiscal year ended Dec. 31, 2017
10-Q
Quarter ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-K
Fiscal year ended Dec. 31, 2016
10-Q
Quarter ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-K
Fiscal year ended Dec. 31, 2015
10-Q
Quarter ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-K
Fiscal year ended Dec. 31, 2014
10-Q
Quarter ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-K
Fiscal year ended Dec. 31, 2013
10-Q
Quarter ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-K
Fiscal year ended Dec. 31, 2012
10-Q
Quarter ended Sept. 30, 2012
10-Q
Quarter ended June 30, 2012
10-Q
Quarter ended March 31, 2012
10-K
Fiscal year ended Dec. 31, 2011
10-Q
Quarter ended Sept. 30, 2011
10-Q
Quarter ended June 30, 2011
10-Q
Quarter ended March 31, 2011
10-K
Fiscal year ended Dec. 31, 2010
10-Q
Quarter ended Sept. 30, 2010
10-Q
Quarter ended June 30, 2010
10-Q
Quarter ended March 31, 2010
10-K
Fiscal year ended Dec. 31, 2009
PROXIES
DEF 14A
Filed on March 22, 2024
DEF 14A
Filed on March 17, 2023
DEF 14A
Filed on March 18, 2022
DEF 14A
Filed on March 19, 2021
DEF 14A
Filed on March 20, 2020
DEF 14A
Filed on March 22, 2019
DEF 14A
Filed on March 19, 2018
DEF 14A
Filed on March 20, 2017
DEF 14A
Filed on March 21, 2016
DEF 14A
Filed on March 23, 2015
DEF 14A
Filed on March 24, 2014
DEF 14A
Filed on March 29, 2013
DEF 14A
Filed on March 5, 2012
DEF 14A
Filed on March 7, 2011
DEF 14A
Filed on March 8, 2010
TABLE OF CONTENTS
Part IItem 1. BusinessItem 1A. Risk FactorsItem 1B. Unresolved Staff CommentsItem 2. PropertiesItem 3. Legal ProceedingsItem 4. Mine Safety DisclosuresPart IIItem 5. Market For The Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases Of Equity SecuritiesItem 6. [reserved]Item 7. Management's Discussion and Analysis Of Results Of Operations and Financial ConditionItem 7A. Quantitative and Qualitative Disclosures About Market RiskItem 8. Financial Statements and Supplementary DataNote 1: Summary Of Significant Accounting Policies and Implementation Of New Financial Accounting StandardNote 2: RevenueNote 3: Acquisitions and DivestitureNote 4: Collaborations and Other ArrangementsNote 5: Asset Impairment, Restructuring, and Other Special ChargesNote 6: InventoriesNote 7: Financial InstrumentsNote 8: Goodwill and Other IntangiblesNote 9: Property and EquipmentNote 10: LeasesNote 11: BorrowingsNote 12: Stock-based CompensationNote 13: Shareholders' EquityNote 14: Income TaxesNote 15: Retirement BenefitsNote 16: ContingenciesNote 17: Other Comprehensive Income (loss)Note 18: Other Net, (income) ExpenseNote 19: Discontinued OperationsItem 9. Changes in and Disagreements with Accountants on Accounting and Financial DisclosureItem 9A. Controls and ProceduresItem 9B. Other InformationItem 9C. Disclosure Regarding Foreign Jurisdictions That Prevent InspectionsPart IIIItem 10. Directors, Executive Officers, and Corporate GovernanceItem 11. Executive CompensationItem 12. Security Ownership Of Certain Beneficial Owners and Management and Related Stockholder MattersItem 13. Certain Relationships and Related Transactions, and Director IndependenceItem 14. Principal Accountant Fees and ServicesItem 15. Exhibits and Financial Statement SchedulesItem 16. Form 10-k Summary

Exhibits

3.1 Amended Articles of Incorporation Incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013 3.2 Bylaws, as amended Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 16, 2021 4.1 Indenture, dated February 1, 1991, between the Company and Deutsche Bank Trust Company Americas, as successor trustee to Citibank, N.A., as Trustee Incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, Registration No. 333-186979 4.2 Tripartite Agreement, dated September 13, 2007, appointing Deutsche Bank Trust Company Americas as Successor Trustee under the Indenture listed in Exhibit 4.1 Incorporated by reference to Exhibit 4.2 to the Company's Annual Report on Form 10-K for the year ended December 31, 2008 4.3 Description of the Company's Common Stock Incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019 4.4 Description of the Company's 1.000% Notes due 2022, 1.625% Notes due 2026, and 2.125% Notes due 2030 Incorporated by reference to Exhibit 4.4 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019 4.5 Description of the Company's 6.77% Notes due 2036 Incorporated by reference to Exhibit 4.5 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019 4.6 Description of the Company's 7 1/8% Notes due 2025 Incorporated by reference to Exhibit 4.6 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019 4.7 Description of the Company's 0.625% Notes due 2031 and 1.700% Notes due 2049 Incorporated by reference to Exhibit 4.7 to the Company's Annual Report on Form 10-K for the year ended December 31, 2019 4.8 Description of the Company's 0.500% Notes due 2033, 1.125% Notes due 2051, and 1.375% Notes due 2061 Attached 4.9 Description of the Company's 1.625% Notes due 2043 Attached 10.1 Amended and Restated 2002 Lilly Stock Plan(1) Incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 10.2 Form of Performance Award under the 2002 Lilly Stock Plan(1) Attached 10.3 Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)(1) Attached 10.4 Form of Performance Award under the 2002 Lilly Stock Plan (non-executive officer)(1) Attached 10.5 Form of Shareholder Value Award under the 2002 Lilly Stock Plan(1) Attached 10.6 Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)(1) Attached 10.7 Form of Shareholder Value Award under the 2002 Lilly Stock Plan (non-executive officer)(1) Attached 10.8 Form of Relative Value Award under the 2002 Lilly Stock Plan(1) Attached 10.9 Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)(1) Attached 10.10 Form of Relative Value Award under the 2002 Lilly Stock Plan (non-executive)(1) Attached 10.11 Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan(1) Attached 10.12 Form of Restricted Stock Unit Award under the 2002 Lilly Stock Plan (with non-compete)(1) Incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 10.13 Release Agreement, effective as of February 9, 2021, by and between Eli Lilly and Company and Joshua L. Smiley(1) Incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 10.14 The Lilly Deferred Compensation Plan, as amended(1) Incorporated by reference to Exhibit 10.5 to the Company's annual report on Form 10-K for the year ended December 31, 2013 10.15 The Lilly Directors' Deferral Plan, as amended(1) Incorporated by reference to Exhibit 10 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 10.16 The Eli Lilly and Company Bonus Plan, as amended(1) Incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020 10.17 The Loxo Oncology, Inc. Bonus Plan(1) Attached 10.18 2007 Change in Control Severance Pay Plan for Select Employees, as amended(1) Incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K for the year ended December 31, 2020 21 List of Subsidiaries Attached 23 Consent of Independent Registered Public Accounting Firm Attached 31.1 Rule 13a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer Attached 31.2 Rule 13a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer Attached 32 Section 1350 Certification Attached